1. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (23rd March 2019) Authors: Veeraraghavan, J; Angelis, C De; Mao, R; Wang, T; Herrera, S; Pavlick, A C; Contreras, A; Nuciforo, P; Mayer, I A; Forero, A; Nanda, R; Goetz, M P; Chang, J C; Wolff, A C; Krop, I E; Fuqua, S A W; Prat, A; Hilsenbeck, S G; Weigelt, B; Reis-Filho, J S Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗